In Regard to Maguire et al

To the Editor: We read the article by Maguire et al (1) with great interest. The authors present a single-arm phase 2 trial of elective nodal dose reduction for patients with locoregionally advanced squamous cell carcinoma of the head and neck (HNSCC). Fifty-four patients were enrolled, with a median follow-up of 36 months. The dose to the elective nodal volume was lowered to 36 Gy. The authors conclude that this approach is feasible and needs to be further investigated in future clinical trials.

https://ift.tt/2spOWAr